Un grupo de más de 120 personas -entre las que figuran médicos, científicos, financiadores y fabricantes- coordinado por la OMS, se dedicará en cuerpo y alma a buscar una vacuna contra la COVID-19. «Aunque lleva tiempo desarrollar una vacuna para uso general, esta podría ser esencial para controlar pandemia. Mientras tanto, aplaudimos las medidas que reducen la propagación del virus y protegen a las personas y nos comprometemos a utilizar el tiempo ganado con la adopción de estas medidas para desarrollar una vacuna lo más rápidamente posible»
Desde que el 7 de enero de 2020, las autoridades chinas identificaron un virus, el SARS-CoV-2, como agente etiológico de esta enfermedad, a la que la OMS dio el nombre de enfermedad por coronavirus 2019 (COVID-19) el 11 de febrero de 2020, el organismo internacional puso en marcha «un plan de investigación y desarrollo (I+D) para acelerar el desarrollo de pruebas diagnósticas, vacunas y terapias para este nuevo coronavirus».
Sin embargo, el ritmo frenético al que se propaga el SARS-CoV-2 y la proliferación de pacientes enfermos de COVID-19 deja claro que el tiempo no juega a favor de la humanidad en esta lucha, más bien al contrario. Por ello, un grupo de más de 120 expertos entre científicos, médicos, productores y financiadores, ha firmado una declaración conjunta en la que se compromete a «ayudar a acelerar la disponibilidad de una vacuna contra la COVID-19″.
Te interesa
Declaración
Si bien este conglomerado de expertos/as internacionales reconoce que «lleva tiempo desarrollar una vacuna para uso general» pero asume que la vacuna podría llegar «para controlar esta pandemia mundial». Así, este cónclave de especialistas aplaude «mientras tanto» las medidas de «intervención comunitaria que reducen la propagación del virus y protegen a las personas, especialmente las poblaciones vulnerables«. Por último, el comunicado que firman más 120 expertos/as de todo el mundo, remarca el compromiso de «utilizar el tiempo ganado con la adopción generalizada de estas medidas para desarrollar una vacuna lo más rápidamente posible»
Signatarios por orden alfabético (en inglés)
Randy A. Albrecht, Icahn School of Medicine at Mount Sinai, USA
Mohamad Assoum, Mercy Global Health
Luigi Aurisicchio, on behalf of Takis Biotech, Italy
Dan Barouch, Center for Virology and Vaccine Research, USA
Trevor Brasel, The University of Texas Medical Branch (UTMB), USA
Jennifer L Bath, ImmunoPrecise Antibodies, Canada
Sina Bavari, Edge BioInnovation Consulting and Management, USA
Maria Elena Bottazzi, Baylor College of Medicine, Houston, USA
Gerhard Beck, Austrian Medicines and Medical Devices, Austria
Tom Brady, Flow Pharma Inc, USA
Kate Broderick, Inovio, USA
Will Brown, Altimmune Inc, USA
Scot Bryson, Orbital Farm, Canada
Ricardo Carrión, Texas Biomedical Research Institute, USA
Miles Carroll, Public Health England, UK
Keith Chappell, University of Queensland, Australia
Daniel S. Chertow, National Institutes of Health, U.S. Department of Health and Human Services, USA
Sandra Cordo, Universidad de Buenos Aires, Argentina
Wian de Jongh, on behalf of the Prevent n-CoV consortium (AdaptVac, ExpreS2ion, Copenhagen University, Leiden University Medical Centre, Wageningen University and Tubingen University)
Natalie Dean, University of Florida, USA
Rafael Delgado, Hospital Universitario 12 de Octubre, Spain
Dimiter Dimitrov
David A. Dodd, GeoVax, Inc., USA
Paul Duprex, Center for Vaccine Research, University of Pittsburgh, USA
Luis Enjuanes; Centro Nacional Biotecnología, Spain
Jeremy Farrar, Josie Golding, Charlie Weller, on behalf of Wellcome Trust, UK
Mark Feinberg, Swati Gupta and Ripley Ballou, on behalf of IAVI, USA
Antonella Folgori, on behalf of ReiThera, Italy
Thomas Friedrich, University of Wisconsin, School of Veterinary Medicine, USA
Simon Funnel, Public Health England, UK
Luc Gagnon, Nexelis, Canada
Adolfo Garcia-Sastre, Icahn School of Medicine at Mount Sinai, USA
Vipin Garg, Altimmune Inc., USA
Volker Gerdts, on behalf of VIDO-Intervac, University of Saskatchewan, Canada
Nora Gerhards, Wageningen Bioveterinary Research, The Netherlands
Christiane Gerke, Head of Vaccine Programs/Head of Vaccine Innovation Development, Institut Pasteur, France
Carlo Giaquinto, Department of Women and Child Health, University of Padova, Italy
Prakash Ghimire, Tribhuvan University, Nepal
Nikolaj Gilbert, Program for Appropriate Technology in Health (PATH), USA
Sarah Gilbert, University of Oxford, UK
Marion F. Gruber, Food and Drug Administration, U.S. Department of Health and Human Services, USA
Farshad Guirakhoo, GeoVax Inc, USA
Bart L Haagmans, Erasmus Medical Center, The Netherlands
M. Elizabeth Halloran, Center for Inference and Dynamics of Infectious Diseases, Fred Hutchinson Cancer Research Center, and University of Washington, USA
Scott Harris, Altimmune Inc, USA
Hideki Hasegawa, National Institute of Infectious Diseases, Japan
Richard Hatchett, on behalf of the Coalition for Epidemic Preparedness Innovations (CEPI), Norway
James Hayward, Applied DNA Sciences, USA
Sheri Ann Hild
Peter Hotez, Baylor College of Medicine, USA
Youngmee Jee, Seoul National University, College of Medicine, Republic of Korea
Charu Kaushic, Institute of Infection and Immunity, Canadian Institutes of Health Research (CHIR), Government of Canada
Alyson A. Kelvin, Dalhousie University, Canada
Larry D. Kerr, Office of Global Affairs, U.S. Department of Health and Human Services, USA
Bernard Kerscher, PEI, Germany
Jae-Ouk Kim, International Vaccine Institute, Republic of Korea
Seungtaek Kim, Institut Pasteur Korea, Republic of Korea
Jason Kindrachuk, University of Manitoba, Canada
Otfried Kistner, Senior Consultant and Independent Vaccine Expert, Austria
Gary Kobinger, Université Laval, Canada
Marion Koopmans, Viroscience Department, Erasmus Medical Centre, The Netherlands
Philip R. Krause, Food and Drug Administration, U.S. Department of Health and Human Services, USA
Greg Kulnis, Nexelis, Canada
Paul Henri Lambert, Centre of Vaccinology, University of Geneva, Switzerland
Nathalie Landry, Medicago Inc., Canada
Roger Le Grand, Inserm-CEA-Université Paris Saclay, France
Robin Levis, Food and Drug Administration, U.S. Department of Health and Human Services, USA
Mark G Lewis, Bioqual Inc, USA
Joshua Liang, Clover Biopharmaceuticals, China
Jinzhong Lin, on behalf of Fudan University, China
Ira Longini, University of Florida, USA
Shabir Madhi, University of the Witwatersrand, Johannesburg, South Africa
Jessica E. Manning, National Institutes of Health, U.S. Department of Health and Human Services, USA
Peter Marks, Director, on behalf of Food and Drug Administration/Center for Biologics Evaluation and Research
Hilary D. Marston, National Institutes of Health, U.S. Department of Health and Human Services, USA
Federico Martinón-Torres, Hospital Clínico Universitario de Santiago de Compostela, Spain
Sebastian Maurer-Stroh, on behalf of the GISAID Initiative
John W. Mellors, University of Pittsburgh School of Medicine, USA
Ali Mirazimi, Department of Laboratory medicin, Karolinska institutet, Sweden
Kayvon Modjarrad, Walter Reed Army Institute of Research, USA
Stefan O. Mueller, CureVac, Germany
Vincent J. Munster, National Institutes of Health, U.S. Department of Health and Human Services, USA
César Muñoz-Fontela, Bernhard-Nocht-Institute for Tropical Medicine, Germany
Aysegul Nalca, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), USA
José Manuel Ochoa, Altimmune Inc., USA
Dave O’Connor, University of Wisconsin-Madison, USA
Lidia Oostvogels, CureVac, Germany
Nisreen M. A. Okba, Erasmus Medical Center, The Netherlands
L. Jean Patterson, National Institutes of Health, U.S. Department of Health and Human Services, USA
Joe Payne, on behalf of Arcturus Therapeutics
Jonathan Pearce, on behalf of the UK Research and Innovation (UKRI) and the Medical Research Council (MRC), UK
Stanley Perlman, University of Iowa, USA
Margaret Louise Pitt, WRAIR/ U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), USA
Anuradha Poonepalli, Health Products Regulation Group, Health Sciences Authority, Singapore
Dieter Pullirsch, Austrian Medicines and Medical Devices Agency, Austria
Damian Purcell, Doherty Institute, Australia
Chuan Qin, Institute of Laboratory Animal Sciences (ILAS), CAMS & PUMC, China
Angela Rasmussen, Columbia University Mailman School of Public Health, USA
Scott Roberts, Altimmune Inc., USA
Estefania Rodriguez, Bernhard Nocht Institute for Tropical Medicine, Germany
Ted M Ross, Center for Vaccines and Immunology, University of Georgia, USA
Chad J Roy, Tulane National Primate Research Center and Tulane School of Medicine, USA
Reid Rubsamen, Flow Pharma Inc, USA
Anna Laura Salvati, Italy
Andrew Satz, EVQLV Inc, USA
Hanneke Schuitemaker and Johan Van Hoof, on behalf of Janssen Pharmaceuticals Companies of Johnson & Johnson, USA
Robert Shattock, Imperial College, UK
John Shriver, Sanofi, USA
Gale Smith, Novavax Inc. USA
Peter Smith, London School of Hygiene and Tropical Medicine, UK
Isabel Sola, Centro Nacional Biotecnología, Spain
James Southern, Adviser to South African Health Products Regulatory Authority
Jonathan M Spergel, Children’s Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania, USA
Sybil Tasker, Codagenix Inc, USA
Chien-Te Kent Tseng, University of Texas Medical Branch, Galveston, Texas, USA
U.S. Department of Health and Human Services, USA, Assistant Secretary for Preparedness and Response/Biodefense Advanced Research and Development Authority
U.S. Department of Health and Human Services, USA, Centers for Disease Control and Prevention
Jean Marie Vianney Habarugira, on behalf of the European & Developing Countries Clinical Trials Partnership (EDCTP)
Veronika von Messling, on behalf of German Federal Ministry of Education and Research, Germany
Tony T. Wang, Food and Drug Administration, U.S. Department of Health and Human Services, USA
Jeffrey Wolf, Heat Biologics Inc, USA
Ningshao Xia, Xiamen University of China, China
Yingjie Xu, on behalf of Shanghai Jiaotong University, China
Paul R Young, University of Queensland, Australia
Hang Yu, on behalf of Shanghai RNACure, China
Xuefeng Yu, CanSino Biologics, China
Tal Zaks, on behalf of Moderna, USA
Peter Daszak, President, EcoHealth Alliance, New York, USA
